| Dr Jason Ryan Pryor, MD | |
|
1906 Belleview Ave Se, Roanoke, VA 24014 | |
| (540) 981-7000 | |
| Not Available |
| Full Name | Dr Jason Ryan Pryor |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 1906 Belleview Ave Se, Roanoke, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316239064 | NPI | - | NPPES |
| Entity Name | Genesis Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477654945 PECOS PAC ID: 7214841436 Enrollment ID: O20031113000044 |
News Archive
The hunt for antivirals has reached an unprecedented pace in light of the coronavirus 2019 (COVID-19) pandemic. The causal agent for this disease – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has already infected over 52 million people worldwide, and has subsequently claimed over 1.3 million lives. However, among the innumerable promising drug candidates that help battle the virus and mitigate its damage, none have yet made it to the clinic.
Coastal Contacts Inc. today announced its financial results for the three months ended January 31, 2010.
A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.
Bristol-Myers Squibb Company is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc.
Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Ryan Pryor, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7000 | Dr Jason Ryan Pryor, MD 1906 Belleview Ave Se, Roanoke, VA 24014 Ph: (540) 981-7000 |
News Archive
The hunt for antivirals has reached an unprecedented pace in light of the coronavirus 2019 (COVID-19) pandemic. The causal agent for this disease – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has already infected over 52 million people worldwide, and has subsequently claimed over 1.3 million lives. However, among the innumerable promising drug candidates that help battle the virus and mitigate its damage, none have yet made it to the clinic.
Coastal Contacts Inc. today announced its financial results for the three months ended January 31, 2010.
A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.
Bristol-Myers Squibb Company is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc.
Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.
› Verified 1 days ago
Kevin Leal, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Camron L Johnson Privitera, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 21 Highland Ave Se, Ste 100, Roanoke, VA 24013 Phone: 540-344-9213 Fax: 540-345-7559 | |
Robert C Gard, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 21 Highland Ave Se, Ste 100, Roanoke, VA 24013 Phone: 540-344-9213 Fax: 540-345-7559 | |
Joseph Tamez, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 4348 Electric Rd, Roanoke, VA 24018 Phone: 540-769-0976 Fax: 540-857-5393 | |
Kaitlyn Bixel, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-224-4635 Fax: 540-985-9099 | |
Susan Smith, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 89 Summers Way, Roanoke, VA 24019 Phone: 540-992-1251 | |
Dr. Erinn E Hokanson, NP Pediatrics Medicare: Medicare Enrolled Practice Location: 4348 Electric Rd, Roanoke, VA 24018 Phone: 540-769-0975 Fax: 540-772-8219 |